Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?

被引:15
作者
Mayerhoefer, Marius E. [1 ]
Giraudo, Chiara [1 ]
Senn, Daniela [1 ]
Hartenbach, Markus [1 ]
Weber, Michael [1 ]
Rausch, Ivo [2 ]
Kiesewetter, Barbara [3 ]
Herold, Christian J. [1 ]
Hacker, Marcus [1 ]
Pones, Matthias [1 ]
Simonitsch-Klupp, Ingrid [4 ]
Muellauer, Leonhard [4 ]
Dolak, Werner [5 ]
Lukas, Julius [6 ]
Raderer, Markus [3 ]
机构
[1] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria
[3] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria
[4] Med Univ Vienna, Inst Pathol, Vienna, Austria
[5] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria
[6] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria
基金
奥地利科学基金会;
关键词
lymphoma; 2-F-18-fluoro-2-deoxy-D-glucose; positron emission tomography; magnetic resonance imaging; computed tomography; DIFFUSION-WEIGHTED MRI; NON-HODGKIN-LYMPHOMA; FDG PET/CT; LESIONS; REPRODUCIBILITY;
D O I
10.1097/RLU.0000000000001005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed-time-point 2-F-18-fluoro-2-deoxy-D-glucose-positron emission tomography (F-18-FDG-PET) performs better than standard-time-point F-18-FDG-PET. Materials and Methods: Patients with untreated histologically verified MALT lymphoma, who were undergoing pretherapeutic F-18-FDG-PET/computed tomography (CT) and consecutive F-18-FDG-PET/magnetic resonance imaging (MRI), using a single F-18-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective F-18-FDG-PET scans at time points 1 (45-60 minutes after tracer injection, TP1) and 2 (100-150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUVmax (maximum standardized uptake values) ratios were also assessed. Results: F-18-FDG-PET at TP1 was true positive in 15 o f 23 involved regions, and F-18-FDG-PET at TP2 was true-positive in 20 of 23 involved regions; no false-positive regions were noted. Accordingly, region-based sensitivities and specificities were 65.2% (confidence interval [CI], 45.73%-84.67%) and 100% (CI, 100%-100%) for F-18-FDG-PET at TP1; and 87.0% (CI, 73.26%-100%) and 100% (CI, 100%-100%) for F-18-FDG-PET at TP2, respectively. FDG-PET at TP1 detected lymphoma in at least one nodal or extranodal region in 7 of 13 patients, and F-18-FDG-PET at TP2 in 10 of 13 patients; accordingly, patient-based sensitivity was 53.8% (CI, 26.7%-80.9%) for F-18-FDG-PET at TP1, and 76.9% (CI, 54.0%-99.8%) for 18F-FDG-PET at TP2. Lesion-to-liver and lesion-to-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 +/- 0.40 and 1.52 +/- 0.62) than at TP2 (ratios, 1.67 +/- 0.74 and 2.56 +/- 1.10; P = 0.003 and P = 0.001). Conclusions: Delayed-time-point imaging may improve F-18-FDG-PET in MALT lymphoma.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 16 条
[11]   Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients [J].
Mayerhoefer, Marius E. ;
Karanikas, Georgios ;
Kletter, Kurt ;
Prosch, Helmut ;
Kiesewetter, Barbara ;
Skrabs, Cathrin ;
Porpaczy, Edit ;
Weber, Michael ;
Pinker-Domenig, Katja ;
Berzaczy, Dominik ;
Hoffmann, Martha ;
Sillaber, Christian ;
Jaeger, Ulrich ;
Muellauer, Leonhard ;
Simonitsch-Klupp, Ingrid ;
Dolak, Werner ;
Gaiger, Alexander ;
Ubl, Philipp ;
Lukas, Julius ;
Raderer, Markus .
CLINICAL CANCER RESEARCH, 2014, 20 (11) :2984-2993
[12]   Diffusion-weighted magnetic resonance imaging of breast lesions: the influence of different fat-suppression techniques on quantitative measurements and their reproducibility [J].
Muertz, P. ;
Tsesarskiy, M. ;
Kowal, A. ;
Traeber, F. ;
Gieseke, J. ;
Willinek, W. A. ;
Leutner, C. C. ;
Schmiedel, A. ;
Schild, H. H. .
EUROPEAN RADIOLOGY, 2014, 24 (10) :2540-2551
[13]  
Park SH, 2015, LEUKEMIA LYMPHOMA, V25, P1
[14]   PET/MR Imaging in the Detection and Characterization of Pulmonary Lesions: Technical and Diagnostic Evaluation in Comparison to PET/CT [J].
Rauscher, Isabel ;
Eiber, Matthias ;
Furst, Sebastian ;
Souvatzoglou, Michael ;
Nekolla, Stephan G. ;
Ziegler, Sibylle I. ;
Rummeny, Ernst J. ;
Schwaiger, Markus ;
Beer, Ambros J. .
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (05) :724-729
[15]   Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma [J].
Shinya, Takayoshi ;
Fujii, Soichiro ;
Asakura, Shoji ;
Taniguchi, Toshitaka ;
Yoshio, Kotaro ;
Alafate, Aierken ;
Sato, Shuhei ;
Yoshino, Tadashi ;
Kanazawa, Susumu .
ANNALS OF NUCLEAR MEDICINE, 2012, 26 (08) :616-621
[16]   18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients [J].
Weiler-Sagie, Michal ;
Bushelev, Olga ;
Epelbaum, Ron ;
Dann, Eldad J. ;
Haim, Nissim ;
Avivi, Irit ;
Ben-Barak, Ayelet ;
Ben-Arie, Yehudit ;
Bar-Shalom, Rachel ;
Israel, Ora .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (01) :25-30